TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss
Retatrutide is an investigational once-weekly injectable agonist of the GIP, GLP-1, and glucagon receptors. It is not approved by the FDA or any regulatory
DO
By Daniel Okafor · Regulatory Correspondent
Oct 28 15:39 ETSource: HCPLive
From the source
Read at hcplive.comTRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss
Retatrutide is an investigational once-weekly injectable agonist of the GIP, GLP-1, and glucagon receptors. It is not approved by the FDA or any regulatory agency.
